TrialThe journal of prevention of Alzheimer's disease2025

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.

Eric Siemers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.